Aptose Biosciences Inc. (TSX: APS)

Market Cap	18.65M
Revenue (ttm)	n/a
Net Income (ttm)	-64.60M
Shares Out	18.11M
EPS (ttm)	-2,136.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,034
Open	1.020
Previous Close	1.020
Day's Range	n/a
52-Week Range	1.000 - 6.900
Beta	1.47
Analysts	n/a
Price Target	31.02 (+2,911.65%)
Earnings Date	Aug 8, 2024

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule,...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. William G. Rice Ph.D.
• Employees: 35
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: APS

Financial Performance

Financial numbers in USD